Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule and an amino acid analog structurally related to glutamine. It acts as an inhibitor of leukotriene A4 hydrolase, the enzyme responsible for converting leukotriene A4 to leukotriene B4 in the arachidonic acid metabolism pathway. Leukotriene B4 is a potent pro-inflammatory mediator involved in various inflammatory diseases. The compound has been studied primarily as a research tool and investigative agent rather than for clinical use, with no approved indications or advanced clinical trials reported[1][6]. Its primary mechanism of action is inhibition of leukotriene A4 hydrolase, potentially modulating inflammatory responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid.